Compare TBPH & WYFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBPH | WYFI |
|---|---|---|
| Founded | 2013 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 993.7M | 806.5M |
| IPO Year | N/A | 2025 |
| Metric | TBPH | WYFI |
|---|---|---|
| Price | $18.67 | $17.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $27.80 | ★ $34.38 |
| AVG Volume (30 Days) | 528.0K | ★ 1.2M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $80,327,000.00 | $70,202,034.00 |
| Revenue This Year | $70.78 | $64.54 |
| Revenue Next Year | N/A | $142.04 |
| P/E Ratio | $32.28 | ★ N/A |
| Revenue Growth | ★ 27.12 | N/A |
| 52 Week Low | $7.90 | $13.91 |
| 52 Week High | $20.33 | $40.75 |
| Indicator | TBPH | WYFI |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | N/A |
| Support Level | $17.25 | N/A |
| Resistance Level | $19.13 | N/A |
| Average True Range (ATR) | 0.65 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 78.72 | 0.00 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Whitefiber Inc is a provider of artificial intelligence infrastructure solutions. The company owns high-performance computing data centers and provide cloud-based HPC graphics processing units services, which it terms cloud services, for customers such as AI application and machine learning developers. Its Tier-3 data centers provide hosting and colocation services. Its cloud services support generative AI workstreams, especially training and inference. It has two reportable segments: cloud services and colocation services. The cloud services segment generates revenue from providing high performance computing services to support generative AI workstreams. Colocation services generate revenue by providing customers with physical space, power and cooling within the data center facility.